Zacks Investment Research
21 Sept 2026, 23:15 UTC · 2h ago
Verdict
Headline leans bullish. We score MEDP +0.30 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.30moderately bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Medpace's projected quarterly earnings per share is $4.45, representing a 15.28% increase year-over-year.
Priced inconsensus estimate for upcoming release
So whatIf the upcoming print misses this $4.45 target, it could trigger a correction toward the industry's lower average P/E.
More positive than 63% of claims this week
The company's full-year revenue is projected to reach $2.84 billion, a 12.38% increase from the prior year.
Continue reading
5 related stories
More positive than 54% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inZacks Consensus Estimates
So whatMeeting this FY target implies maintaining a quarterly revenue run-rate of approximately $710 million.
More positive than 50% of claims this week
Medpace is trading at a Forward P/E ratio of 34.91, compared to an industry average of 17.31.
Priced incurrent valuation metrics
So whatThe stock trades at a 101% premium to its peers, increasing vulnerability to any guidance downgrade.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 54% of ticker scores this week
The company showed a daily gain outperforming the S&P 500 and has positive projected growth for EPS and revenue.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
MEDP hasn't traded since this ran. Last close $624.20 (Sep 21); the reaction starts at the next open.
MEDP chart →